Benzofuranylpropylaminopentane – (260550-89-8)

Benzofuranylpropylaminopentane (BPAP) is an experimental drug that acts as a potent monoaminergic activity enhancer (MAE). It is structurally related to selegiline and phenylpropylaminopentane (PPAP), with a benzofuran ring replacing the benzene ring in PPAP.

BPAP enhances the release of serotonin, norepinephrine, and dopamine by stimulating nerve impulse propagation in the brain. Unlike psychostimulants such as amphetamine, which induce an uncontrolled release of neurotransmitters, BPAP only increases the amount of neurotransmitter released when a neuron is stimulated. At higher concentrations, BPAP also acts as a monoamine reuptake inhibitor, with a higher affinity for dopamine and norepinephrine transporters than for the serotonin transporter.

BPAP has been studied for its potential clinical applications in treating Parkinson’s disease, Alzheimer’s disease, depression, and aging. It has also shown neuroprotective effects and the ability to slow age-related monoaminergic neurodegeneration in animal models.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Benzofuranylpropylaminopentane
https://pubchem.ncbi.nlm.nih.gov/compound/9816303
https://pmc.ncbi.nlm.nih.gov/articles/PMC4525045/